Fate Therapeutics Inc (NASDAQ:FATE)

52.82
BATS BZX Real-Time Price
As of 12:40pm ET
 +0.06 / +0.11%
Today’s Change
48.31
Today|||52-Week Range
121.16
-41.91%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$5.0B

Company Description

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Contact Information

Fate Therapeutics, Inc.
12278 Scripps Summit Drive
San Diego California 92131
P:(858) 875-1800
Investor Relations:

Employees

Shareholders

Individual stakeholders8.14%
Mutual fund holders53.37%
Other institutional44.85%

Top Executives

J. Scott WolchkoPresident, Chief Executive Officer & Director
Edward J. DulacChief Financial Officer & Accounting Officer
Bahram ValamehrChief Research & Development Officer
Wen Bo WangSenior Vice President-Technical Operations
Yu Waye ChuSenior Vice President-Clinical Development